Why McKesson Stock Soared More Than 5% Higher Today
The arrangement is now in force through June 2032. McKesson also reaffirmed its guidance for the current fiscal year.
Stock Taper 
MCK
$906.03
▲ UP 0.42% (3.75)
KEY STATISTICS
Market Cap$105.64 B
52w High$999.00
52w Low$723.68
Dividend Yield0.41%
FrequencyQuarterly
P/E22.20
Volume67.08K
Shares Out.117.08M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Brian S. Tyler
COMPENSATION 2026
Salary$1,591,667
Stock Awards$17,201,202
Incentive Plan Pay$4,456,668
All Other Comp.$963,507
Total$24,213,044
ABOUT
SECTOR
Healthcare
WENT PUBLIC
November 10, 1994
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
42,300
PRICE TARGET
Target High$1050.00
Target Low$845.00
Target Median$966.50
Target Consensus$953.00
UPCOMING EARNINGS
DateNov 4, 2026
DayWednesday
Rev. Est.$109.87B
NOV
4
WED
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 1998-01-05 | Forward | 2:1 |
ETFS HOLDING THIS STOCK
ETFS HOLDING
977
LISTED HERE
10
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
51.33%
HOLDERS
2,719
TOP 8 OF 2,719 · RANKED BY POSITION SIZE
PRICE
$906.03 ▲ UP 0.42% (+$3.75)About McKesson Corporation
https://www.mckesson.com ↗McKesson Corporation, founded in 1833 and headquartered in Texas, provides healthcare services globally through segments including pharmaceutical distribution, medical-surgical supplies, international distribution, and prescription technology solu...
INDUSTRY
Medical - Distribution
A PRODUCT MCKESSON CORPORATION IS KNOWN FOR
Foster & Thrive
Foster & Thrive, McKesson's private label of over 270 OTC health and wellness products, consolidates Health Mart and Sunmark lines, highlighting the company's focus on the consumer health market.
McKesson in 2025
SENTIMENT: + POSITIVE
RESTRUCTURING · MAY 8, 2025
McKesson Announces Plan to Spin Off Medical-Surgical Unit, Reports Strong Q4 Earnings and Upbeat 2026 Forecast
On May 8, 2025, McKesson announced its intention to separate its Medical-Surgical Solutions segment into a new, independent publicly traded company. This major strategic pivot was revealed alongside a strong fourth-quarter and full-year fiscal 2025 earnings report, which saw a 64% increase in adjusted earnings per share for the quarter, and a robust profit forecast for fiscal 2026.
DIVESTITURE · MAY 2025 · ANNOUNCED
McKesson to Spin Off $11.4B Medical-Surgical Unit to Sharpen Focus on High-Margin Oncology and Biopharma
In a major strategic pivot, McKesson announced its intention to separate its Medical-Surgical Solutions segment into a new, independent public company. This move is designed to unlock shareholder value and allow McKesson to concentrate its resources and capital on its higher-growth, higher-margin businesses, particularly in specialty pharmaceuticals, oncology, and biopharma services.
Latest News
EARLIER COVERAGE
Stock Market Midday, Oct. 1: Stocks Edge Lower as Treasury Yields Surge to 24-Year High
Bond yields hit their highest level in two decades, pressuring blue chip dividend stocks and weighing on the broader market, today, Oct. 1, 2026.
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032. “We are pleased to extend our long-standing, strategic relationship with CVS Health and continue supporting their important role in serving patients and communities across the country,” said Brian T.
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
McKesson (MCK) reached $853.81 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow5
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book1
Overall Score3
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 5
OVERWEIGHT 3
OUTPERFORM 2
SECTOR PERFORM 1
EQUAL WEIGHT 1
NEUTRAL 1
13 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 VRTX | $504.73 | COMPARE |
 BMY | $61.15 | COMPARE |
 MDT | $86.38 | COMPARE |
 CVS | $86.46 | COMPARE |
 SYK | $275.43 | COMPARE |
 SNY | $39.92 | COMPARE |
 GSK | $47.03 | COMPARE |
 HCA | $426.69 | COMPARE |
TRADES BY CONGRESS
HOUSE TRADES
Ro Khanna
Purchase
2026-08-10
Richard Ray Larsen
Purchase
2026-07-08
Jonathan Jackson
Sale (Full)
2026-06-15
Elizabeth Fletcher
Sale
2026-04-08
INSIDER TRADES
★
OFFICER: SVP, CONTROLLER & CAO
Rutledge Napoleon B JR
Sale · 111 shares
2026-09-08
★
DIRECTOR
Lerman Bradley E
Sale · 301 shares
2026-08-10
★
OFFICER: EVP AND CHIEF STRATEGY OFFICER
Srinivasan Ramesh (NMN)
Purchase · 368 shares
2026-08-07
★
OFFICER: EVP AND CHIEF STRATEGY OFFICER
Srinivasan Ramesh (NMN)
— · 316 shares
2026-08-01